Give the 13-valent pneumococcal conjugate vaccine to senior patients Give the 13-valent pneumococcal conjugate vaccine along with the 23-valent pneumococcal polysaccharide vaccine to all patients aged ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

September 7, 2010 — Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a report in the September 3 issue of MMWR. Morbidity and ...

RAHWAY, N.J., September 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating ...

(HealthDay News) – A model shows that replacing the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults “Pneumococcal disease continues to pose a significant risk for adults in Europe, among adults who are 65 or ...

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 ...